Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: Results of a Delphi survey

TY - JOUR

T1 - Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis

T2 - Results of a Delphi survey

AU - Funke-Chambour, Manuela

AU - Albera, Carlo

AU - Bendstrup, Elisabeth

AU - Costabel, Ulrich

AU - Grutters, Jan C.

AU - Harari, Sergio

AU - Johannson, Kerri A.

AU - Kreuter, Michael

AU - Strambu, Irina

AU - Vancheri, Carlo

AU - Varone, Francesco

AU - Vitulo, Patrizio

AU - Wuyts, Wim A.

AU - Martinez, Fernando

AU - Raghu, Ganesh

N1 - Funding Information: Conflict of interest: M. Funke-Chambour reports grants from Roche, grants and personal fees for advisory board work from Boehringer Ingelheim, outside the submitted work. C. Albera reports personal fees for advisory board work, consultancy and steering committee work from Roche, MSD and Bayer, personal fees for advisory board work and consultancy from Boheringer Ingelheim, Fibrogen and GSK, grants from Roche and Boheringer Ingelheim, during the conduct of the study. E. Bendstrup reports grants, personal fees and non-financial support from Boehringer Ingelheim and Hoffmann la Roche, outside the submitted work. U. Costabel reports personal fees for consultancy and lectures, and non-financial support from Boehringer and Roche, personal fees for consultancy from Fibrogen, Pliant Therapeutics and Bristol-Myers Squibb, personal fees for lectures from AstraZeneca and Novartis, outside the submitted work. J.C. Grutters has nothing to disclose. S. Harari reports personal fees for lectures and advisory board work from Roche, grants and personal fees for lectures and advisory board work from Actelion and Boehringer Ingelheim, outside the submitted work. K.A. Johannson reports personal fees, non-financial support and other (advisory board work) from Boehringer Ingelheim, personal fees from Hoffman-La Roche Ltd, Blade Therapeutics and Theravance, grants from The Chest Foundation, University of Calgary Cumming School of Medicine, UCB Biopharma SPRL and Pulmonary Fibrosis Society of Calgary, personal fees and non-financial support from Three Lakes Foundation, outside the submitted work. M. Kreuter reports grants and personal fees from Boehringer Ingelheim and Roche, personal fees from Galapagos, outside the submitted work. I. Strambu reports personal fees for advisory board work and lectures from Boehringer Ingelheim, personal fees for lectures from Roche Pharma, AstraZeneca and Novartis, personal fees for investigation work from Galapagos, outside the submitted work. C. Vancheri reports grants and personal fees from Roche and Boehringer Ingelheim, outside the submitted work. F. Varone reports personal fees from Boehringer Ingelheim and Roche, outside the submitted work. P. Vitulo has nothing to disclose. W.A. Wuyts reports grants from Roche and Boehringer Ingelheim, outside the submitted work (paid to institution). F. Martinez reports personal fees for advisory board work, non-financial support for travel and other from AstraZeneca, other (steering committee work and publication) from Afferent/Merck, personal fees for advisory board work, data monitoring committee work, steering committee work and lectures, non-financial support for travel and other (publication) from Boehringer Ingelheim, other (teleconference without compensation) from Bristol Myers Squibb and twoXR, other (travel support) from Chiesi, personal fees for lectures and non-financial support for travel from Canadian Respiratory Society, CME Outfitters, Inova Fairfax, MDMagazine, NYP Methodist Hospital Brooklyn, Miller Communications, National Association for Continuing Education, Novartis, Peer View, Rare Diseases Healthcare Communications and WebMD/MedScape, personal fees for advisory board work and non-financial support for travel from CSL Behring, Sanofi/Regeneron, University of Birmingham Alabama, Sunovion and Teva, personal fees for lectures from Dartmouth University, France Foundation, New York University, Rockpointe Communications and Vindico, personal fees for advisory board work from Gala, Pearl and Verona, personal fees for data monitoring committee and advisory board work, and non-financial support for travel from Genentech, grants, personal fees for advisory board, data monitoring committee and steering committee work, and non-financial support for travel from GlaxoSmithKline, other (steering committee without compensation) from Nitto, personal fees for steering committee work and non-financial support for travel from Patara/Respivant, personal fees for educational activities from Physicians Education Resource and UpToDate, personal fees for steering committee work from ProMedior, other (data monitoring and steering committee without compensation) from Biogen, non-financial support (steering committee) from Veracyte, non-financial support for travel and in-kind study support from Zambon, non-financial support (consultancy and in-kind study support) from ProTerrix Bio, personal fees for consultancy from IQVIA, Raziel and Abvie, outside the submitted work. G. Raghu reports personal fees and other (consultancy) from Boerhinger Ingelheim, Roche, Respivant and Veracyte, other (consultancy and data monitoring committee work) from Avalyn, other (consultancy) from BMS, Biogen, Blade Therapeutics, Bellerophan, Fibrogen, Gilead, Genentech, Nitto and Promedior, and grants from NIH, outside the submitted work.

PY - 2021

Y1 - 2021

UR - https://www.scopus.com/pages/publications/85105895411

U2 - 10.1183/13993003.04219-2020

DO - 10.1183/13993003.04219-2020

M3 - Letter

C2 - 33419886

AN - SCOPUS:85105895411

SN - 0903-1936

VL - 57

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 4

M1 - 2004219

ER -